| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12-1 |
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study
|
Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L |
| 國立成功大學 |
2024-12 |
DERMATOLOGISTS' PERSPECTIVES AND REAL-WORLD ASSESSMENT OF ALOPECIA AREATA SEVERITY AMONG ADULTS IN TAIWAN
|
Chen;Cc;Yang;Cc;Lin;S;Austin;J;Kurosky;S;Hanson;Ka;Yen;M;Anderson;P;Encinas;Ga;Marwaha;S;Chen;A;Chung;Wh |
| 國立成功大學 |
2024-12 |
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
|
Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A. |
| 國立成功大學 |
2024-12 |
Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39
|
Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B. |
| 國立成功大學 |
2024-12 |
Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39
|
Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B. |
| 國立成功大學 |
2024-12 |
Collisional-Radiative modeling of unresolved transition array spectra near 200AA from W17+-W25+ emissions for diagnostics of ITER edge plasma
|
Nishimura;R;Oishi;T;Murakami;I;Kato;D;Sakaue;H, A.;Gupta;S;Ohashi;H;Goto;M;Kawamoto;Y;Kawate;T;Takahashi;H;Tobita;K |
| 國立成功大學 |
2024-12 |
ARE DIFFERENT GENERATIONS OF CERAMIC-ON- CERAMIC IMPLANTS MORE COST-EFFECTIVE THAN METAL-ON-POLYETHYLENE IMPLANTS IN PRIMARY TOTAL HIP ARTHROPLASTY?
|
Ku;L, J.;Huang;Y;Tai;T, W.;Hsu;S, H.;Ling;D;Wang;J, D. |
| 國立成功大學 |
2024-12 |
Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39
|
Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B. |
